Why Is KPTI Stock Dropping Today? Karyopharm Falls After Loan Default and Dilutive Forbearance Deal

Karyopharm Therapeutics (KPTI) shares fell 13.56% in pre-market trading on Thursday after the company missed a $15.8 million term-loan payment and secured a forbearance agreement that includes a dilutive convertible preferred-stock issuance.

The liquidity crisis comes at a critical juncture for the biopharmaceutical company, which is advancing a supplemental new drug application for its myelofibrosis program.

What Happened?

Karyopharm failed to make the term-loan payment due on September 10, 2026. Rather than face an immediate default, the company negotiated parallel forbearance agreements with three creditor groups: the lenders under its Credit Agreement, holders of its 2028 and 2029 notes, and its revenue interest investors.

The agreements pause specified enforcement actions through the earlier of October 15, 2026 or certain trigger events. During the forbearance period, a default-rate interest surcharge of an additional 2% applies to the term loan and unpaid note interest.

As forbearance consideration, Karyopharm agreed to issue $20 million in newly created 0% convertible perpetual preferred stock. Each share is priced at $1,000 and convertible at $1.62 per share, subject to a 19.99% issuance cap pending stockholder approval by March 15, 2027.

Why Does The Deal Raise Concerns?

The $1.62 conversion price sits below the company's current pre-market price of $1.46, meaning existing common shareholders face meaningful dilution if and when the preferred stock converts. The 19.99% cap, measured on a fully diluted basis, represents a significant portion of the outstanding share count for a company already trading at depressed levels.

The deal also signals the company's strained liquidity. Karyopharm's cash position stood at approximately $65.4 million as of its most recent quarterly report, against near-term obligations that included the $15.8 million loan payment and ongoing operating costs for a company with no significant product revenue.

According to the forbearance agreement, the arrangements are intended to buy time for Karyopharm to advance its myelofibrosis program and explore financings or strategic alternatives. That language suggests management views the current capital structure as unsustainable without a near-term catalyst.

What Should Investors Watch Next?

The October 15 forbearance deadline is the immediate inflection point. If Karyopharm cannot secure permanent financing or a strategic transaction before then, creditors could resume enforcement actions, potentially including acceleration of the term loan.

The company's sNDA for selinexor combined with ruxolitinib in frontline myelofibrosis, submitted in August 2026, remains the most credible path to value creation. The Phase 3 SENTRY trial met its first co-primary endpoint for spleen volume reduction but fell short on the second co-primary endpoint for symptom improvement — a mixed data set that may influence both FDA decisions and any potential strategic buyer's valuation.

Management previously outlined a target of potential approval and launch as early as Q1 2027, with U.S. peak revenue of up to $1 billion. Whether that timeline holds, and whether a priority review is granted, will shape investor sentiment in the weeks ahead.

Pre-market liquidity is thinner than regular-session trading, so the full magnitude of today's move may not be clear until the market opens. With the forbearance clock ticking and the $1.62 conversion price looming as overhang, the regular session will show whether investors view this as a temporary bridge or the first step toward a more fundamental restructuring.